Phospho-PRK1 (Thr774) + PRK2 (Thr816) + PRK3 (Thr718) Polyclonal Antibody, RBITC Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-3347R-RBITC-100uL |
| Product Name | Phospho-PRK1 (Thr774) + PRK2 (Thr816) + PRK3 (Thr718) Polyclonal Antibody, RBITC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Dog, Cow, Pig, Horse, Rabbit |
| Specifications | |
| Conjugation | RBITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human PRK1 around the phosphorylation site of Thr774 |
| Modification Site | Thr816 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 5585 |
| Subcellular location | Cytoplasm, Nucleus, Cell membrane |
| Synonyms | Prokineticin-1/Endocrine-gland-derived vascular endothelial growth factor; PROK1; EGVEGF; PK1; EG-VEGF; PRK1. |
| Background | Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) induces proliferation, migration, and fenestration in capillary endothelial cells derived from endocrine glands. EG-VEGF possesses an HIF-1 binding site; its expression is induced by hypoxia and restricted to the steroidogenic glands (ovary, testis, adrenal and placenta). Expression of EG-VEGF is often complementary to the expression of VEGF, suggesting that these molecules function in a coordinated manner. EG-VEGF is an example of a class of highly specific mitogens that act to regulate proliferation and differentiation of the vascular endothelium in a tissue-specific manner. It is expressed primarily in one type of tissue and acts selectively on one type of endothelium. EG-VEGF, possibly through binding to a G protein-coupled receptor, results in the activation of MAPK p44/42 and phosphatidylinositol 3-kinase signaling pathways, leading to proliferation, migration and survival of responsive endothelial cells . |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is Phospho-PRK1 (Thr774) + PRK2 (Thr816) + PRK3 (Thr718) Polyclonal Antibody, RBITC Conjugated (bs-3347R-RBITC) validated for, and at what dilution?
bs-3347R-RBITC is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-3347R-RBITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise Phospho-PRK1 (Thr774) + PRK2 (Thr816) + PRK3 (Thr718) Polyclonal Antibody, RBITC Conjugated (bs-3347R-RBITC)?
KLH conjugated synthetic phosphopeptide derived from human PRK1 around the phosphorylation site of Thr774
What are the excitation and emission wavelengths of the RBITC conjugate (bs-3347R-RBITC)?
RBITC on bs-3347R-RBITC: excitation / emission 540nm/625nm.